Durability Still In Question For Acadia's Nuplazid In Alzheimer’s Psychosis
Full Phase II data studying Acadia's Nuplazid (pimavanserin) in patients with Alzheimer’s disease psychosis confirmed the exploratory drug met its primary endpoint, but worries remain over the drug's durability – and hence its commercial promise in dementia-related psychosis.
You may also be interested in...
Alkermes revealed successful completion of its third Phase III trial for the depression drug ALKS 5461 as well as a risky plan to seek FDA approval based on two negative and one positive late-stage study.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.